Bain Capital Life Sciences Investors, LLC
Q3 2026 13F-HR Holdings
Net value change ($000)
-192,180
(-11.4%)
New positions
4
Sold out positions
2
Turnover %
22.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ADARX PHARMACEUTICALS INC | 134,176 | NEW |
| TARS | 86,168 | NEW |
| FREENOME INC | 37,256 | NEW |
| DYN | 30,609 | NEW |
| ALKERMES PLC | 26,140 | 25.7% |
| AVIR | 1,162 | 12.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|